Skip to content
capsule

Orforglipron

emergingOral

First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.


Key facts
Classification
Capsule — First oral non-peptide GLP-1 agonist in late-stage trials.
Primary benefits
Fat Loss (9/10) · Gut Health (3/10)
Administration
Oral
Doses studied
12-36-120 mg oral daily in the morning. Titrate up gradually.
Evidence strength
Emerging
Quick stats
Type
Capsule
Administration
Oral
Studies referenced
0
Stacks with
0 peptides
Goal coverage · Orforglipron
🔥 Fat Loss9/10
🫃 Gut Health3/10
FIG.1  Modeled goal coverage from reviewed studies. Score out of 10.
From our network:Cornerstone Peptide